ENDV — Endonovo Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.18m
- $7.24m
- $0.14m
Annual income statement for Endonovo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.083 | 0.31 | 0.166 | 0.073 | 0.135 |
| Cost of Revenue | |||||
| Gross Profit | 0.07 | 0.217 | 0.1 | 0.058 | 0.125 |
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.93 | 4.05 | 3.63 | 2.28 | 3.04 |
| Operating Profit | -3.84 | -3.74 | -3.47 | -2.2 | -2.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.44 | -17.3 | -0.396 | -3.1 | -18.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.44 | -17.3 | -0.396 | -3.1 | -18.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.44 | -17.3 | -0.396 | -3.1 | -18.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.44 | -17.3 | -0.396 | -3.1 | -18.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -18.6 | -24.9 | 0.013 | -0.052 | -0.135 |